EXEL Exelixis Earnings and EPS analysis
- Stocks
- Healthcare
- NASDAQ: EXEL
- Earnings
EPS in 2025 (TTM): $2.46
Last Report Period Date: Sep 30, 2025
As of November 2025, according to Exelixis's latest financial report, the company's current EPS (TTM) is $2.46. In 2024, the company recorded an earnings per share (EPS) of $1.8, which represents an increase compared to its EPS of $0.65 in 2023. Exelixis's earnings per share for the quarterly report ending on Sep 30, 2025 was $0.72.
EXEL earnings history
The annual EPS in 2024 was $1.8, an increase of 176.9% from $0.65 in 2023. For the quarter ending Sep 30, 2025, the EPS was $0.72, showing a 75.6% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of September 2025 is $2.46. In 2023, the annual EPS was $0.65, showing an increase of 14% from 2022.
EXEL EPS growth
Over the last 12 months, Exelixis has registered an EPS growth of 75.6% (YoY, quarterly). Over a three-year span, the company had an average EPS growth of 35.1% per year. Over the last 5 years, the company had an average EPS growth rate of 11.2%.
EXEL Earnings Waterfall
EXEL Earnings vs Peers
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| MRK Merck & Co Inc | 13.14 | 4,728.6% | 9.4% | 12% |
| PFE Pfizer Inc | 14.49 | 273.7% | -28.7% | -13.2% |
| BMY Bristol Myers Squibb Co | 15.54 | -213.7% | N/A | N/A |
| EXEL Exelixis Inc | 16.47 | 176.9% | 35.1% | 11.2% |
| JNJ Johnson & Johnson | 17.85 | -57.9% | -9.7% | 0.4% |
| AMGN Amgen Inc | 24.33 | -39.3% | -9.7% | -10.1% |
| CRIS Curis Inc | N/A | 23.2% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.